Cartesian Therapeutics Overview
Valuation check: RNAC's PEG ratio is 11.87, above the Healthcare sector average of 2.56.
Get informed when a big investor buys or sells
+ Follow11.87
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for RNAC is 11.87. That is above the Healthcare sector average of 2.56. Investors often review this figure alongside Cartesian Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, RNAC currently prints 11.87 for PEG ratio, while the sector average sits near 2.56. That is roughly 363.9% above the sector mean. Large gaps often invite a closer look at Cartesian Therapeutics's growth, margins, and balance sheet.
A PEG ratio of 11.87 for Cartesian Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (2.56) and with RNAC's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting RNAC's PEG ratio (11.87), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Cartesian Therapeutics's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
